ERNAW
Ernexa Therapeutics Inc. Warrants
NASDAQ · Financial Services · Asset Management · US
$0.04
−8.13%Income statement
| Metric | TTM | 2025 |
|---|---|---|
| Revenue | ||
| Total Revenue | — | — |
| Cost of Revenue | 280.0K | 263.0K |
| Gross Profit | (280.0K) | (263.0K) |
| Operating Expenses | ||
| R&D Expense | 4.8M | 4.2M |
| SG&A Expense | 5.1M | 4.9M |
| General & Admin Expense | — | — |
| Selling & Marketing Expense | — | — |
| Other Expenses | — | — |
| Total Operating Expenses | 9.9M | 9.1M |
| Cost and Expenses | 10.1M | 9.3M |
| Operating Income (EBIT) | (10.1M) | (9.3M) |
| Non-Operating | ||
| Interest Income | 95.0K | 83.0K |
| Interest Expense | — | 27.0K |
| Net Interest Income | 95.0K | 56.0K |
| Other Non-Op Income/Expense | (1.3M) | (4.8M) |
| Non-Operating Income (excl Interest) | — | — |
| EBT (Pre-Tax Income) | (11.5M) | (14.1M) |
| Income Tax Expense | (93.0K) | (45.0K) |
| Bottom Line | ||
| Net Income | (11.4M) | (14.1M) |
| Earnings from Cont. Ops | (11.4M) | (14.1M) |
| Earnings from Discont. Ops | — | — |
| Bottom Line Net Income | (11.4M) | (14.1M) |
| Per Share | ||
| Basic EPS | ($30.72) | ($55.89) |
| Diluted EPS | ($30.72) | ($55.89) |
| Revenue Per Share | $0.00 | $0.00 |
| Shares | ||
| Basic Shares Outstanding | 792000 | 252280 |
| Diluted Shares Outstanding | 792000 | 252280 |
| Profitability Metrics | ||
| EBITDA | (9.9M) | (9.1M) |
| D&A | 280.0K | 263.0K |
| EBIT | (10.1M) | (9.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026